Abstracts tagged "Autoimmune Skin Disease"

Abstract Number: 775 • 2019 ACR/ARP Annual Meeting
Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin
Jessica Turnier¹, Celine Berthier ¹, Lam Tsoi ¹, Lori Lowe ¹, Gabrielle Morgan ², Johann Gudjonsson ¹, Lauren Pachman ² and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago
Background/Purpose: Skin inflammation can herald systemic disease manifestations and disease chronicity in juvenile myositis (JM), yet we lack an understanding of the pathogenic mechanisms driving…
Abstract Number: 1939 • 2019 ACR/ARP Annual Meeting
Analysis of Discoid Lupus Erythematosus (DLE) Gene Expression Reveals Dysregulation of Pathogenic Pathways Associated with Infiltrating Immune/Inflammatory Cells
Frances Harris¹, Sarah Heuer ², Robert Robl ², Prathyusha Bachali ², Adam Labonte ², Benjamin Chong ³, Michelle Catalina ², Peter Lipsky ² and Amrie Grammer ², ¹RILITE Research Institute, Charlottesville, VA, ²RILITE Research Institute, Charlottesville, ³University of Texas Southwestern, Dallas
Background/Purpose: DLE is a chronic, scarring inflammatory autoimmune disease of the skin. The precise molecular pathways underlying DLE pathogenesis have not been fully delineated. To…
Abstract Number: 99 • 2018 ACR/ARHP Annual Meeting
DC-Hil+ Myeloid-Derived Suppressor Cells Are Elevated in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients
Stephanie Florez-Pollack¹, Lin-chiang Tseng¹, Masato Kobayashi¹, Gregory Hosler^1,2, Kiyoshi Ariizumi¹ and Benjamin F. Chong¹, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Propath, Dallas, TX
Background/Purpose: Myeloid derived suppressor cells (MDSCs) are major T cell suppressors, and their dysfunction has been implicated in the pathophysiology of autoimmune diseases. MDSCs suppress…
Abstract Number: 2040 • 2013 ACR/ARHP Annual Meeting
Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria
Clifton O. Bingham III¹, Marilyn Towns¹ and Susan J. Bartlett², ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Associations between chronic urticaria (CU) with autoantibodies and other autoimmune conditions have implicated T cells in CU initiation and/or propagation. Many patients (pts) have…
Abstract Number: 1935 • 2013 ACR/ARHP Annual Meeting
Validation Of The Cutaneous Dermatomyositis Disease Area and Severity Index: Characterizing Severity and Assessing Responsiveness To Clinical Change
Cynthia O. Anyanwu^1,2, David Fiorentino³, Lorinda Chung⁴, Yanli Wang⁵, Kathleen J. Propert⁶ and Victoria P. Werth^7,8, ¹Department of Dermatology, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁵Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁶Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁷Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ⁸Department of Dermatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Translational research and clinical trials necessitate validated outcome measures to reliably assess disease progression and treatment efficacy. The Cutaneous Dermatomyositis Disease Area and Severity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].